Focus on

Renal damage by dronedarone
Focus Farmacovigilanza 2013;74(1):3
Dronedarone is an antiarrhythmic drug approved by the EMA in 2009 for the treatment of some types of atrial fibrillation.[1] The EMA scientific report, to support the marketing authorization, states that the medicine is less effective but safer than amiodarone. Safety profile The pre-marketing...
[more]
Drug-induced taste and smell disorders
Focus Farmacovigilanza 2013;74(1):2
Taste and smell alterations induced by medicines are quite common in the clinical practice with an estimated incidence ranging between 2 and 5%. Many drugs (or drugs classes) have been associated to these kind of adverse reactions, among them: ACE-inhibitors, betalattamic antibiotics, biguanides,...
[more]
Botulinum toxin adverse effects
Focus Farmacovigilanza 2012;73(11):2
Clostridium botulinum, anaerobic gram positive bacteria, produces seven different types of toxins, named with alphabet letters from A to G. In clinical practice (Table 1) only toxin A (Botox®, Vistabex®, Dysport®) and B (Neurobloc®) are used. These drugs contain a complex of real toxin and a non-...
[more]

Pages